

DISCUSSIONS WITH LEADERS

- 1821** **Oncologist, Business Leader, and Investor Arie S. Belldegrun Discusses a Career in Innovative Medical Entrepreneurship**
Arie S. Belldegrun, Ken Herrmann, and Johannes Czernin

THE STATE OF THE ART

- 1824** **Modeling PET Data Acquired During Nonsteady Conditions: What If Brain Conditions Change During the Scan?**
Evan D. Morris, Gaele M. Emvalomenos, Jocelyn Hoye, and Steven R. Meikle

CONTINUING EDUCATION

- 1838** **Precision Oncology in Melanoma: Changing Practices**
Sean C. Dougherty, William L. Flowers, and Elizabeth M. Gaughan

IS IT REALLY HAPPENING?

- 1846** **The Translation of Dosimetry into Clinical Practice: What It Takes to Make Dosimetry a Mandatory Part of Clinical Practice**
Manuel Bardiès, Glenn Flux, and Katarina Sjögren Gleisner

EDITORIALS

- 1848** **Feasibility of ¹⁷⁷Lu-PSMA Administration as Outpatient Procedure for Prostate Cancer**
Federico Zagni, Luigia Vetrone, Andrea Farolfi, Maria Vadalà, Elisa Lodi Rizzini, Arber Golemi, Lidia Strigari, and Stefano Fanti
- 1850** ■ **INVITED PERSPECTIVE. Changed Regulation Enables Pragmatic Solution for Cancer Patients**
Uwe Holzwarth
- 1851** **Challenges with ¹⁷⁷Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical Practice**
Hossein Jadvar, Amir Iravani, Lisa Bodei, and Jeremie Calais

ONCOLOGY

Clinical

- 1855** **Impact of ¹⁸F-FDG PET/MRI on Therapeutic Management of Women with Newly Diagnosed Breast Cancer: Results from a Prospective Double-Center Trial**
Kai Jannusch, Lale Umutlu, Julian Kirchner, Nils-Martin Bruckmann, Janna Morawitz, Ken Herrmann, Wolfgang Peter Fendler, Ann-Kathrin Bittner, Oliver Hoffmann, Svyetlana Mohrmann, et al.
- 1862** **Kinetic Analysis and Metabolism of Poly(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted ¹⁸F-Fluorothantrate PET in Breast Cancer**
Anthony J. Young, Austin R. Pantel, Mahsa Kiani, Robert K. Doot, Sina Bagheri, Daniel A. Pryma, Michael D. Farwell, Shihong Li, Hsiaoju Lee, Erin K. Schubert, et al.

- 1869** **[¹⁸F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy**
Jelena Levi, Millie Das, Minal S. Vasawala, Deepti Behl, Martin Pomper, Patrick M. Forde, Erica Nakajima, James Sayre, Bin Shen, Hilda Cabrera, et al.

- 1876** **International Metabolic Prognostic Index Is Superior to Other Metabolic Tumor Volume-Based Prognostication Methods in a Real-Life Cohort of Diffuse Large B-Cell Lymphoma**
Vibeke K.J. Vergote, Gregor Verhoef, Ann Janssens, F.J. Sherida H. Woei-a-jin, Wies Deckers, Annouschka Laenen, Thomas Tousseyn, Daan Dierickx, and Christophe M. Deroose

- 1884** **Value of [⁶⁸Ga]Ga-NYM046 PET/CT, in Comparison with ¹⁸F-FDG PET/CT, for Diagnosis of Clear Cell Renal Cell Carcinoma**
Kequan Lou, Jialiang Wang, Huihui He, Yanjuan Wang, Yuanyuan Mi, Wenjin Li, Liping Chen, Yu Zhang, Yong Mao, Jianguo Lin, et al.

- 1891** **CD70-Targeted Immuno-PET/CT Imaging of Clear Cell Renal Cell Carcinoma: A Translational Study**
Xiang Zhou, Qianyun Wu, Wei Zhai, You Zhang, Yanfei Wu, Min Cao, Cheng Wang, Yihui Guan, Jianjun Liu, Fang Xie, et al.

- 1899** **[¹⁸F]FDG and [⁶⁸Ga]Ga-FAPI-04-Directed Imaging for Outcome Prediction in Patients with High-Grade Neuroendocrine Neoplasms**
Kerstin Michalski, Aleksander Kosmala, Philipp E. Hartrampf, Marieke Heinrich, Sebastian E. Serfling, Wiebke Schlötterburg, Andreas K. Buck, Alexander Meining, Rudolf A. Werner, and Alexander Weich

Basic

- 1904** ■ **FEATURED BASIC SCIENCE ARTICLE. Immuno-PET/CT Imaging of Trop2 with [¹⁸F]AIF-RESCA-T4 Differentiates Lung Cancer from Inflammation**
Wei Huang, Min Cao, Yanfei Wu, You Zhang, Shuxian An, Xinbing Pan, Xinyuan Zhou, Hongda Shao, Yihui Guan, Gang Huang, et al.

THERANOSTICS

Clinical

- 1911** ■ **FEATURED ARTICLE OF THE MONTH. Intraarterial Administration of Peptide Receptor Radionuclide Therapy in Patients with Advanced Meningioma: Initial Safety and Efficacy**
Adriana Amerein, Christoph Maurer, Malte Kircher, Alexander Gäble, Anne Kriebold, Andreas Rinscheid, Oliver Viering, Christian H. Pfob, Ralph A. Bundschuh, Lars Behrens, et al.
- 1917** **Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with ²¹³Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors**
Andreas Helisch, Clemens Kratochwil, Christian Kleist, Susanne Krämer, Juan Jose Rosales Castillo, Katharina Dendl, Hendrik Rathke, Isabelle von Goetze, Mathias Schreckenberger, Dirk Jäger, et al.

1923 Clinical, Pathologic, and Imaging Variables Associated with Prostate Cancer Detection by PSMA PET/CT and Multiparametric MRI

Ida Sonni, Adam B. Weiner, Sahith Doddipalli, Madhvi Deol, David Ban, Hye Ok Kim, Tristan Grogan, Preeti Ahuja, Nashla Barroso, Yang Zong, et al.

1932 Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [¹⁷⁷Lu]Lu-PSMA-617

Miguel Muniz, Oliver Sartor, Jacob J. Orme, Regina M. Koch, Hana R. Rosenow, Ahmed M. Mahmoud, Jack R. Andrews, Adam M. Kase, Irbaz B. Riaz, Gokce Belge Bilgin, et al.

1939 Comparison of Posttherapy 4- and 24-Hour [¹⁷⁷Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer

Mina Swiha, Sarennya Pathmanandavel, Nathan Papa, Zahra Sabahi, Sherrington Li, Alex Zheng, Sobia Khan, Maria Ayers, Shikha Sharma, Megan Crumbaker, et al.

1945 SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving [¹⁷⁷Lu]-PSMA-617

Ridvan Arda Demirci, Roman Gulati, Jessica E. Hawley, Todd Yezefski, Michael C. Haffner, Heather H. Cheng, Robert B. Montgomery, Michael T. Schweizer, Evan Y. Yu, Peter S. Nelson, et al.

1952 FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study

Rong Rong Huang, Chunlai Zuo, Christine E. Mona, Adrien Holzgreve, Colm Morrissey, Peter S. Nelson, Lauren Brady, Lawrence True, Anthony Sisk, Johannes Czernin, et al.

ENDOCRINOLOGY

Clinical

1959 Improved Localization of Insulinomas Using ⁶⁸Ga-NODAGA-Exendin-4 PET/CT

Marti Boss, Olof Eriksson, Kirsi Mikkola, Annemarie Eek, Maarten Brom, Mijke Buitinga, Adrienne H. Brouwers, Irina Velikyan, Beatrice Waser, Saila Kauhanen, et al.

RADIOCHEMISTRY

Basic

1965 ■ SPECIAL CONTRIBUTION. MIRD Pamphlet No. 31: MIRDcell V4—Artificial Intelligence Tools to Formulate Optimized Radiopharmaceutical Cocktails for Therapy

Sumudu Katugampola, Jianchao Wang, Roger W. Howell, Rachel Marie Barbee, Alejandro Bertolet, Wesley E. Bolch, Yuni K. Dewaraja, William D. Erwin, Valentina Ferri, Roger W. Howell, et al.

PHYSICS AND INSTRUMENTATION

Basic

1974 Performance Characteristics of a New Generation 148-cm Axial Field-of-View uMI Panorama GS PET/CT System with Extended NEMA NU 2-2018 and EARL Standards

Haiqiong Zhang, Chao Ren, Yu Liu, Xinchun Yan, Meixi Liu, Zhixin Hao, Haiqun Xing, and Li Huo

THE ILLUSTRATED POST

1983 CT Enhancement of a Nasal Leech After Thrombectomy

Kaiwu Meng and Dian He

LETTERS TO THE EDITOR

1984 One Bite from the Apple, One Bite from the Orange in the PRECISE-MDT Study

Andrei Fodor, Cristiano Pini, Gaia Ninatti, Nadia Di Muzio, and Arturo Chiti

1985 Limitations of Retrospective Study Design and Potential Bias in the PRECISE-MDT Study

Tadashi Watabe

1986 ■ Reply. One Bite from the Apple, One Bite from the Orange in the PRECISE-MDT Study and Limitations of Retrospective Study Design and Potential Bias in the PRECISE-MDT Study

Matteo Bauckneht, Francesco Lanfranchi, and Liliana Belgioia

DEPARTMENTS

6A This Month in JNM

7A SNMMI Leadership Update